7/18/2022

Verapamil Extended-Release Tablets

Products Affected - Description

- Calan SR extended release tablet, Pfizer, 180 mg, bottle, 100 count, NDC 00025-1911-31 - discontinued
- Calan SR extended release tablet, Pfizer, 240 mg, bottle, 100 count, NDC 00025-1891-31 - discontinued
- Calan SR extended release tablet, Pfizer, 240 mg, bottle, 500 count, NDC 00025-1891-51 - discontinued
- Verapamil hydrochloride extended release tablet, Mylan, 120 mg, bottle, 100 count, NDC 00378-2120-01 - discontinued
- Verapamil hydrochloride extended release tablet, Mylan, 120 mg, unit-dose blister pack, 100 count, NDC 51079-0894-20 - discontinued
- Verapamil hydrochloride extended release tablet, Mylan, 180 mg, bottle, 100 count, NDC 00378-2180-01 - discontinued
- Verapamil hydrochloride extended release tablet, Mylan, 180 mg, bottle, 500 count, NDC 00378-2180-05 - discontinued
- Verapamil hydrochloride extended release tablet, Mylan, 180 mg, unit-dose blister pack, 100 count, NDC 51079-0899-20 - discontinued
- Verapamil hydrochloride extended release tablet, Mylan, 240 mg, bottle, 90 count, NDC 00378-1411-77 - discontinued
- Verapamil hydrochloride extended release tablet, Mylan, 240 mg, bottle, 100 count, NDC 00378-1411-01 - discontinued
- Verapamil hydrochloride extended release tablet, Mylan, 240 mg, bottle, 500 count, NDC 00378-1411-05 - discontinued
- Verapamil hydrochloride extended release tablet, Mylan, 240 mg, unit-dose blister pack, 100 count, NDC 51079-0869-20 - discontinued

Reason for the Shortage

- Glenmark has verapamil extended-release tablets available.
- Mylan discontinued verapamil extended-release tablets in June 2021.
- Pfizer has Calan SR tablets available.

Available Products

- Calan SR extended release tablet, Pfizer, 120 mg, bottle, 100 count, NDC 00025-2712-31
- Calan SR extended release tablet, Pfizer, 180 mg, bottle, 100 count, NDC 00025-2818-31
- Calan SR extended release tablet, Pfizer, 240 mg, bottle, 100 count, NDC 00025-2924-31
- Verapamil hydrochloride extended release tablet, Glenmark, 120 mg, bottle, 100 count, NDC 68462-0292-01
- Verapamil hydrochloride extended release tablet, Glenmark, 180 mg, bottle, 100 count, NDC 68462-0293-01
- Verapamil hydrochloride extended release tablet, Glenmark, 180 mg, bottle, 500 count, NDC 68462-0293-05
- Verapamil hydrochloride extended release tablet, Glenmark, 240 mg, bottle, 100 count, NDC 68462-0260-01
- Verapamil hydrochloride extended release tablet, Glenmark, 240 mg, bottle, 500 count, NDC 68462-0260-05

Updated

Updated July 18, 2022 by Anthony Trovato, PharmD, BCPS. Created April 11, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.